It can be concluded through this review that low-dose IL2 therapy is a safe treatment modality for patients with SLE or RA; not just because of the low risk of serious adverse effects of the treatment itself, but also because this therapy induces immune tolerance by correcting the immune dysregulation that led to the disease in the first place. Here, IL2 is linked to systemic lupus erythematosus.